Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Dupixent is used in children ages 6 months and ... CRwNP in children ages 12 years and older eosinophilic or corticosteroid-dependent asthma in children ages 6 years and older For more information ...

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal ...

In the first draft guidance NICE acknowledged that Dupixent is effective for preventing exacerbations in people with severe asthma with type 2 inflammation, compared with standard care.

autoinjector pen severe eosinophilic asthma 12 years and older Dupilumab (Dupixent) Interleukin-4Rα prefilled syringe, autoinjector pen severe eosinophilic asthma 6 years and older Mepolizumab ...

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.

Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and ...

Medically reviewed by Casey Gallagher, MD Atopic dermatitis (the most common type of eczema) causes dry, itchy skin with ...

Mar. 12, 2025 — A lung function test used to help diagnose asthma works better in the morning, becoming less reliable throughout the day, researchers have found. Using real world data from 1,600 ...